#ClinicalTrial EAQ221CD/CONCURxP monitors CDK4/6 inhibitor medication use with text message reminders & alerts for patients treated for #BreastCancer. For more information: https://bit.ly/EAQ221CD #bcsm cc: @GelarehSadigh, @ilana_graetz
Kudos to @kpthrive/ Kaiser Permanente-Fremont for becoming a new enrolling site for #ClinicalTrial EA5182. This study explores AZD9291 (#Osimertinib) with or without #Bevacizumab as initial treatment for patients with EGFR-mutant #LungCancer. https://bit.ly/ea5182 #LCSM
.@Dr_AmerZeidan of @SmilowCancer & @YaleCancer is leading clinical study EA9171, testing if adding a new drug to the usual treatment for chronic myelogenous #leukemia could help patients. Learn more: https://bit.ly/ea9171-study #CML #leusm
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
Active Clinical Trials
Participating Institutions
International Sites
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).